At a glance
ClinicalIndex Comparison Record- ✓Cytohistological confirmation required for cancer diagnosis
- ✓Age above 18 years with estimated survival over 3 months
- ✓Child-Pugh class A or B with ECOG score <2
- ✓Tolerable coagulation function or reversible coagulation disorders
- ✕Participation in clinical trials within 4 weeks
- ✕Ascites, hepatic encephalopathy, or esophageal and gastric varices bleeding
- ✕Serious accompanying diseases affecting prognosis (heart disease, uncontrolled diabetes, psychiatric disorders)
- ✕Other malignancies or past medical history of malignancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
In Brief
A Phase 3 clinical trial evaluating Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy for Hepatocarcinoma and 9 related conditions. Currently recruiting, targeting 200 participants across 1 site.
Detailed Summary
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
Study Details
Timeline
Interventions
vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.